On Tuesday, Pacira BioSciences, Inc. (NASDAQ:PCRX) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is a ...
PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...
-- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE ...
In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
In Florida, more than 5 million adults are living with arthritis 1 – one of the highest rates in the nation. Of the various types of arthritis, the most common is osteoarthritis (OA), a degenerative ...
Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results